Navigation Links
Igenica Appoints Mary Haak-Frendscho, Ph.D., as Chief Executive Officer
Date:9/18/2012

BURLINGAME, Calif., Sept. 18, 2012 /PRNewswire/ -- Igenica, Inc., a leading biopharmaceutical company focused on the discovery and development of first-in-class cancer antibody therapeutics, today announced the appointment of Mary Haak-Frendscho, Ph.D., to the role of Chief Executive Officer and member of the Board of Directors. Dr. Haak-Frendscho succeeds David Goeddel, Ph.D., who remains as Igenica's Chairman of the Board.

Dr. Haak-Frendscho brings more than twenty years of experience in building robust biotechnology organizations for the discovery and development of novel therapeutic antibodies. Dr. Haak-Frendscho joins Igenica from Takeda, where she served as founding President and Chief Scientific Officer of Takeda San Francisco, establishing and overseeing Takeda's Center of Excellence for antibody biologics. Prior to Takeda, Dr. Haak-Frendscho held positions of increasing responsibility at XOMA, Abgenix and Genentech, where she secured collaborative relationships with external corporate partners, led antibody programs, and played a key role in the development of omalizumab (Xolair®, Genentech/ Novartis).  An immunologist by training, Dr. Haak-Frendscho holds degrees from the University of Michigan,Washington University, Stony Brook University (S.U.N.Y.), and the University of Wisconsin.

"Dr. Haak-Frendscho brings an exceptional range of experience and skills spanning antibody drug discovery and development, operations, strategic alliances and executive management," said Dr. Goeddel. "Her team-oriented approach will serve Igenica well as it transitions into its next stage of growth."

"I am delighted to be joining Igenica at this pivotal time in the company's history," said Dr. Haak-Frendscho.  "With strong support from The Column Group, 5AM Ventures, Orbimed Advisors and Third Rock Ventures, Igenica is well-positioned to be a powerhouse in target and antibody discovery exemplified by an exciting lead program, established discovery platforms and superb management team and scientific staff."

About Igenica, Inc.
Igenica, Inc. is a biopharmaceutical company pioneering breakthrough antibody-based cancer medicines. The company has integrated innovative technology platforms to address the major challenges to developing effective treatments for multiple oncology indications, with sTAg, a new approach to discovering and prioritizing novel tumor antigens, and iTAb, a functional in vivo antibody screening approach. Collectively, the two technology platforms drive Igenica's drug discovery efforts and promise to identify novel and more effective cancer therapeutics.

Igenica's Board of Directors includes David Goeddel, Ph.D., Managing Partner, The Column Group; John Diekman, Ph.D., Managing Partner, 5AM Ventures; Mark A. Goldsmith, M.D., Ph.D., Venture Partner, Third Rock Ventures; Carl Gordon, Ph.D., CFA, General Partner, Orbimed Advisors; Robert Schreiber, Ph.D., Alumni Endowed Professor of Pathology and Immunology, Professor of Molecular Microbiology and Tumor Immunology Program Leader for the Siteman Comprehensive Cancer Center at Washington University School of Medicine.

Contact:

John K. Celebi, MBA
Chief Business Officer
Igenica, Inc.
(650) 231-4320


'/>"/>
SOURCE Igenica, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Igenica Closes $33 Million in Series C Funding
2. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
3. Circassia Appoints Stewart Sharpe as Vice President Commercial Operations
4. Pharmalink Consulting Appoints Chief Operating Officer for the Americas
5. STAAR Surgical Appoints Charles Slacik To Its Board Of Directors
6. EvaluatePharma Appoints Alexander Karle as COO
7. AMRI Appoints Michael Nolan Vice President, Chief Financial Officer and Treasurer
8. Insmed Appoints Will Lewis as President and Chief Executive Officer
9. Circassia Appoints Dr Brett Haumann as Chief Medical Officer
10. Kinex Pharmaceuticals Appoints Mr. Patrick Gallagher Vice President of Business Development and Investor Relations
11. Islet Sciences Appoints Dr. Kevan Herold and Dr. Morton Printz to Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... Aug. 7, 2017 Insightin Health, provider ... retention, and engagement, announced the selection of ... Product Development, effective as of February 2017. In this ... implementation strategy for our clients. Wood brings with ... consulting and business analytics within the healthcare industry. ...
(Date:8/4/2017)... ROCKVILLE, Md. , Aug. 4, 2017 ... during or shortly after a physician/patient consult has long ... industry, and was a notable focus of the largest ...  This is according to healthcare market research firm Kalorama ... of care testing (POCT) offerings or related supplies and ...
(Date:8/2/2017)...  Life Flight Network and PeaceHealth Oregon Network announced they ... and operational efficiency for patients at hospitals in ... Cottage Grove , and Florence, Oregon ... Flight Network work collaboratively to move patients who require the ... time sensitive emergency exists. ...
Breaking Medicine Technology:
(Date:8/16/2017)... Lewisville, TX (PRWEB) , ... August 16, 2017 , ... ... in the United States, named Dr. Douglas J. Harrison, as the new Medical Director ... will be the new facility Medical Director of our Sienna Plantation location,” said Dr. ...
(Date:8/16/2017)... ... , ... “God Will Break Every Chain”: an inspirational story for those shackled by the chains ... author, Evangelist Joann Shivers, a writer and a woman of great faith and wisdom. ... early age. She was born and raised in Vero Beach, Florida and has dedicated ...
(Date:8/15/2017)... ... August 15, 2017 , ... The first study to ... multiple myeloma has been completed, with the team’s findings now published online ahead of ... , Director of the Blood and Marrow Transplant Program at Roswell Park Cancer Institute, ...
(Date:8/15/2017)... ... August 15, 2017 , ... Progressive Dental, a leading ... on the 2017 Fast 50 list of Fastest Growing Companies in Tampa Bay. The ... area who has shown three consecutive years of growth. For this year’s award, Progressive ...
(Date:8/15/2017)... ... August 15, 2017 , ... Dr. Timothy Davis ... periodontal disease . This information can be used to develop patient-specific treatment ... The two salivary diagnostic tests, named MyPerioPath® and MyPerioID® are offered by OralDNA® ...
Breaking Medicine News(10 mins):